Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution.
about
Relationships of the antiproliferative proteins BTG1 and BTG2 with CAF1, the human homolog of a component of the yeast CCR4 transcriptional complex: involvement in estrogen receptor alpha signaling pathwaySuppression of estrogen receptor-mediated transcription and cell growth by interaction with TR2 orphan receptorEstrogen regulation of cyclin E2 requires cyclin D1 but not c-MycDown-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cellsThe p53-estrogen receptor loop in cancerTherapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure.Hormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal WomenEstrogen signaling in the proliferative endometrium: implications in endometriosisTherapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer.Underdeveloped uterus and reduced estrogen responsiveness in mice with disruption of the estrogen-responsive finger protein gene, which is a direct target of estrogen receptor alpha.Induction of estrogen receptor-alpha and -beta activities by synthetic progestins.Inhibition of human breast cancer cell growth by blockade of the mevalonate-protein prenylation pathway is not prevented by overexpression of cyclin D1.Functional ablation of pRb activates Cdk2 and causes antiestrogen resistance in human breast cancer cellsCyclin D mediates tolerance of genome-doubling in cancers with functional p53.The cyclin-like protein, SPY1, regulates the ERα and ERK1/2 pathways promoting tamoxifen resistance.Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cellsLiganded ERα Stimulates the E3 Ubiquitin Ligase Activity of UBE3C to Facilitate Cell Proliferation.Effect of estrogen receptor β agonists on proliferation and gene expression of ovarian cancer cellsp21WAF1/CIP1 selectively controls the transcriptional activity of estrogen receptor alpha.c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry.Cell cycle regulators: mechanisms and their role in aetiology, prognosis, and treatment of cancer.pp60(v-src) induction of cyclin D1 requires collaborative interactions between the extracellular signal-regulated kinase, p38, and Jun kinase pathways. A role for cAMP response element-binding protein and activating transcription factor-2 in pp60(v-Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor.Non-transcriptional action of oestradiol and progestin triggers DNA synthesis.Disruption of TGF-beta growth inhibition by oncogenic ras is linked to p27Kip1 mislocalization.Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts.Progesterone inhibits estrogen-induced cyclin D1 and cdk4 nuclear translocation, cyclin E- and cyclin A-cdk2 kinase activation, and cell proliferation in uterine epithelial cells in miceUncoupling between phenotypic senescence and cell cycle arrest in aging p21-deficient fibroblastsMultifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 functionRheb activates AMPK and reduces p27Kip1 levels in Tsc2-null cells via mTORC1-independent mechanisms: implications for cell proliferation and tumorigenesis.ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance.Lycopene inhibition of cell cycle progression in breast and endometrial cancer cells is associated with reduction in cyclin D levels and retention of p27(Kip1) in the cyclin E-cdk2 complexes.MACROD2 overexpression mediates estrogen independent growth and tamoxifen resistance in breast cancers.Defects in G1-S cell cycle control in head and neck cancer: a review.Polycomb protein SCML2 regulates the cell cycle by binding and modulating CDK/CYCLIN/p21 complexes.5-hydroxytryptamine 2B receptor regulates cell-cycle progression: cross-talk with tyrosine kinase pathwaysEarly increase in cyclin-D1 expression and accelerated entry of mouse hepatocytes into S phase after administration of the mitogen 1, 4-Bis[2-(3,5-Dichloropyridyloxy)] benzene.New insights on the role of hormonal therapy in ovarian cancerHigh miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer.Towards a dietary prevention of hereditary breast cancer.
P2860
Q24290687-81676558-DFA9-47CB-B96F-44C24E85EFAAQ24300794-A29C257E-8AEE-4019-8043-6EDC858841C0Q24653031-0BE2EF12-5150-44AB-A85B-7640857F8FBBQ24672087-38B598A1-18E0-4184-A80F-D95108AFA0FEQ27027865-03D9EEA6-C12E-42A0-9159-99B6529C8D1EQ27851564-544BB1E1-EF67-446A-841F-1B04920907E7Q28077637-FDAC347B-0FF7-4696-AEBA-1B54B1281FBEQ28079639-7024F496-106D-40F1-B29F-A1E5F6B5FB10Q30419997-E619A931-F38B-4074-9F1D-15DBD67C4E6BQ30789721-239A9A49-D970-484F-9912-C2182B4AF94FQ31389362-5E8AC3CE-DE46-4C1D-9057-70A6209EA653Q31957656-EF5C1DFB-8836-45DA-B797-358D5FD7B65FQ33308716-F5105A70-6A2B-470B-883F-B0BFFE53E5CCQ33564829-61CC0DF6-23EB-4F97-9B05-58A06ED1A68BQ33618677-ACA5B891-C173-4199-90B6-A90D17AE8E10Q33630829-3152252E-ADD4-4E85-A4FC-A4888F6820F3Q33631509-A3A39450-DC45-47E4-82A5-C8D5CD8AE408Q33651509-574C6B73-225F-4518-9CA6-9C39A866093EQ33707571-A376EF35-51BD-406B-BA68-C101C675FB5BQ33775134-F7B16435-5D20-4EF8-A2D0-A9BC9247C58EQ33822845-082DA051-D994-441F-82B3-90418B096050Q33854336-48B3A419-9A2D-4DBE-8D95-C81F57E0DFBEQ33888599-EE11AE26-AC8A-4FBD-8088-1BA1976B05DEQ33890864-F79F0A6D-7DB5-4D3D-9DD2-D8ED97CB38F7Q33929011-4495957D-89AA-4CD4-9F7B-EACD62B791D9Q33957508-23AAB70B-C694-4E86-91DC-36962887FC9FQ33957539-A2DA5B11-CF3B-4E2C-9A5A-41236367FDEBQ33965486-5938506D-0F5A-4447-A0C0-25BC7FC6B070Q33967106-AA8A8FD5-5050-4FA9-9229-CD63375D749DQ34136234-D1B2A6F6-478A-4EF1-9D65-A546509AECEFQ34345868-14A5A7FC-183F-4055-87A9-30BFCC7D3B88Q34515989-99EAD03B-49C3-43A8-9F05-574B022E760AQ34708926-D580CF86-C95D-4567-B8AE-3077B7024DA5Q34733424-7EDBD055-7BB6-4227-B46E-323016A6569FQ35072444-6A17ED1B-E49D-4549-A648-1E160D60C7BCQ35077547-74513649-C789-42DA-9437-37E8589F6342Q35793445-5A307C6C-38AD-4DFC-B6C1-FFE50BB4BACBQ36001247-8D6045BF-8C1A-46D5-82A4-9A5F3B9AAE2CQ36070061-F1AFD4CA-2946-4C7A-AEAE-108135F326C9Q36114761-AA46F328-37A5-44B2-8ACC-4405AA2738FC
P2860
Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution.
@ast
Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution.
@en
type
label
Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution.
@ast
Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution.
@en
prefLabel
Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution.
@ast
Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution.
@en
P2860
P356
P1476
Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution.
@en
P2093
Planas-Silva MD
Weinberg RA
P2860
P304
P356
10.1128/MCB.17.7.4059
P407
P577
1997-07-01T00:00:00Z